Supplementary material to:

Standardised comparison of limonene-derived monoterpenes identifies structural determinants of anti-inflammatory activity

Cátia Sousa^{a,b,c}, Alcino Jorge Leitão^{a,b,c}, Bruno Miguel Neves^d, Fernando Judas^{a,c,e}, Carlos Cavaleiro^{b,f}, Alexandrina Ferreira Mendes^{a,b,c *}

Affiliations:

^aCenter for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal
^bFaculty of Pharmacy, University of Coimbra, Coimbra, Portugal
^cCentre for Innovative Biomedicine and Biotechnology, University of Coimbra, Coimbra, Portugal
^dDepartment of Medical Sciences and Institute of Biomedicine – iBiMED, University of Aveiro, Aveiro, Portugal
^eOrthopaedics Department and Bone Bank, University and Hospital Center of Coimbra, Coimbra, Portugal
^fChemical Process Engineering and Engest Products Research Centre Chemical Engineering

^fChemical Process Engineering and Forest Products Research Centre, Chemical Engineering Department, Faculty of Sciences and Technology, University of Coimbra, Coimbra, Portugal

Figure S1









Figure S1. Evaluation of the cytotoxicity of the test compounds. Raw 264.7 cells were treated with the indicated concentrations of the each compound or with the vehicle (0.1% DMSO, control, Ctrl) for 18 h. Each column represents the mean \pm SEM of, at least, three independent experiments. $^{\#}p \le 0.05$, $^{\#}p \le 0.01$, $^{\#\#\#}p \le 0.001$ and $^{\#\#\#}p \le 0.0001$ relative to Ctrl. The dotted line represents the threshold (70% of maximal viability) below which cytotoxicity is recognized, in agreement with standard ISO 10993-5.

Figure S2







Figure S2. Evaluation of the cytotoxicity of the test compounds in the presence of bacterial lipopolysaccharide (LPS). Raw 264.7 cells were treated with LPS, 1 µg/mL, for 18 h, following pretreatment for 1 h with the indicated concentrations of the test compounds or with vehicle (0.1% DMSO, Ctrl). Each column represents the mean ± SEM of ,at least, three independent experiments. *p \leq 0.05, **p \leq 0.01, ***p \leq 0.001 and ****p \leq 0.0001 relative to LPS-treated cells. *p \leq 0.05, **p \leq 0.001 relative to Ctrl. The dotted line represents the threshold (70% of maximal viability) below which cytotoxicity is recognized, in agreement with standard ISO 10993-5.

Figure S3



Uncropped blots shown in Figure 2b

The membranes were cut at ≈ 100 kDa so that the upper piece was incubated with anti-NOS2 antibody and the lower one with the anti- β -Tubulin I antibody.

(S)-(+)-carvone (4)

Uncropped blots shown in Figure 3b





This membrane was also incubated with anti-COX2 antibody and the corresponding band appears near the 75 kDa molecular weight marker.



Uncropped blots shown in Figure 4b





The membranes were cut at ≈ 75 kDa so that the upper piece was incubated with anti-NOS2 antibody and the lower one with the anti- β -Tubulin I antibody.





The membrane was cut between 100-75 kDa and 48 kDa so that the upper piece was incubated with anti-NOS2 antibody, the middle piece with anti- β -Tubulin I antibody and the lower one with the anti-IL-1 β antibody.

Figure S3: Uncropped images of the blots shown in figures 2-5.

Nº	Trivial name	IUPAC name of major isomer	Purity (%)*	Isomer composition	Catalog #, Vendor
1	(S)-(-)-limonene	(4S)-1-methyl-4-prop-1-en- 2-ylclyclohexene	≥95%**	Purum	#62130, Sigma- Aldrich Co.
2	(R)-(+)-limonene	(4R)-1-methyl-4-prop-1-en- 2-yl-cyclohexene	≥99%	Purum	#62118, Sigma- Aldrich Co.
3	(1S,2S,4R)-(+)- limonene-1,2-diol	(1S,2S,4R)-1-methyl-4- prop-1-en-2-ylcyclohexane- 1,2-diol	≥97%	Purum	#669768, Sigma- Aldrich Co.
4	(S)-(+)-carvone	(5S)-2-methyl-4-prop-1-en- 2-ylcyclohex-2-en-1-one	≥96% * *	Purum	#435759, Sigma- Aldrich Co.
5	(R)-(-)-carvone	(5R)-2-methyl-4-prop-1-en- 2-ylcyclohex-2-en-1-one	98%	Purum	#124931, Sigma- Aldrich Co.
6	(-)-carveol	(1R,5R)-2-methyl-5-prop-1- en-2-ylcyclohex-2-en-1-ol (1S,5R)-2-methyl-5-prop-1- en-2-ylcyclohex-2-en-1-ol	≥98%	Mixture of isomers	#61370, Sigma- Aldrich Co.
7	(+)-dihydrocarvone	(2R,5R)-2-methyl-5-prop-1- en-2-ylcyclohexan-1-one (2S,5R)-2-methyl-5-prop-1- en-2-ylcyclohexan-1-one	≥98%	Mixture of isomers	#09164, Sigma- Aldrich Co.
8	(+)-dihydrocarveol	(1S,2S,5S)- 2-methyl-5- prop-1-en-2-ylcyclohexan-1- ol	≥95%	Mixture of isomers – composition: n, ~ 75% iso, ~ 6% neo, ~ 3% neoiso, ~ 1.3%	#37277, Sigma- Aldrich Co.
9	(-)-dihydrocarveol	(1R,2R,5R)- 2-methyl-5- prop-1-en-2-ylcyclohexan-1- ol	≥95%	Mixture of isomers – composition: n, ~ 75% iso, ~ 6% neo, ~ 3% neoiso, ~ 1.3%	#37278, Sigma- Aldrich Co.

10	(+)-isopulegol	(1S,2R,5S)-5-methyl-2-prop- 1-en-2-ylcyclohexan-1-ol	≥99%	Purum	#59765, Sigma- Aldrich Co.
11	(-)-isopulegol	(1R,2S,5R)-5-methyl-2-prop- 1-en-2-ylcyclohexan-1-ol	≥99%	Purum	#59770, Sigma- Aldrich Co.
12	(R)-(+)-pulegone	(5R)-5-methyl-2-propan-2- ylidienecyclohexan-1-one	≥98.5%	Purum	#82569, Sigma- Aldrich Co.
13	(S)-(-)-pulegone	(5S)-5-methyl-2-propan-2- ylidienecyclohexan-1-one	98%	Purum	#328847, Sigma- Aldrich Co.
14	(-)-menthone	(2S,5R)-5-methyl-2-propan- 2-ylcyclohexan-1-one	≥99%	Purum	#63677, Sigma- Aldrich Co.
15	(-)-menthol	(1R,2S,5R)-5-methyl-2- propan-2-ylcyclohexan-1-ol	≥99%	Purum	#63660, Sigma- Aldrich Co.
16	β-myrcene	7-methyl-3-methylideneocta- 1,6-diene	$\ge 90\%$	Purum	#64643, Sigma- Aldrich Co.
17	<i>p</i> -cymene	1-methyl-4-propan- 2ylbenzene	≥99.5%	Purum	#30039, Sigma- Aldrich Co.
18	carvacrol	2-methyl-5-propan-2ylphenol	≥97%	Purum	#22051, Sigma- Aldrich Co.
19	thymol	5-methyl-2-propan-2ylphenol	98%	Purum	#30433, BDH

*Purity relative to sum of enantiomers determined by gas chromatography

**The purities of (1) (96.9%) and (4) (96.8%), which were in stock at our lab for over a year, were confirmed by

GC-MS prior to starting the experiments and found to be within the limits defined by the manufacturer.